{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:24:28Z","timestamp":1778628268048,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Acid sphingomyelinase deficiency (ASMD) or Niemann\u2013Pick disease types A, A\/B, and B is a progressive, life-limiting, autosomal recessive disorder caused by sphingomyelin phosphodiesterase\u00a01 (<jats:italic>SMPD1<\/jats:italic>) gene mutations. There is a need to increase the understanding of morbidity and mortality across children to adults diagnosed with ASMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational retrospective survey analysed medical records of patients with ASMD with retrievable data from 27 hospitals in France, diagnosed\/followed up between 1<jats:sup>st<\/jats:sup>January 1990 and 31<jats:sup>st<\/jats:sup>December 2020. Eligible records were abstracted to collect demographic, medical\/developmental history, and mortality data. Survival outcomes were estimated from birth until death using Kaplan\u2013Meier survival analyses; standardised mortality ratio (SMR) was also explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 118 medical records of patients with ASMD (type B [<jats:italic>n<\/jats:italic>\u2009=\u200994], type A [<jats:italic>n<\/jats:italic>\u2009=\u200915], and type A\/B [<jats:italic>n<\/jats:italic>\u2009=\u20099]) were assessed. The majority of patients were males (63.6%); the median [range] age at diagnosis was 8.0 [1.0\u201318.0] months (type A), 1.0 [0\u20133] year (type A\/B), and 5.5 [0\u201373] years (type B). Overall, 30 patients were deceased at the study completion date; the median [range] age at death for patients with ASMD type A (<jats:italic>n<\/jats:italic>\u2009=\u200914) was 1 [0\u20133.6] year, type A\/B (<jats:italic>n<\/jats:italic>\u2009=\u20096) was 8.5 [3.0\u201330.9] years, and type B (<jats:italic>n<\/jats:italic>\u2009=\u200910) was 57.6 [3.4\u201374.1] years. The median [95% confidence interval (CI)] survival age from birth in patients with ASMD type A and type A\/B was 2.0 [1.8\u20132.7] years and 11.4 [5.5\u201318.5] years, respectively. Survival analysis in ASMD type B was explored using SMR [95% CI] analysis (3.5 [1.6\u20135.9]), which showed that age-specific deaths in the ASMD type B population were 3.5 times more frequent than those in the general French population. The causes of death were mostly severe progressive neurodegeneration (type A: 16.7%), cancer (type B: 16.7%), or unspecified (across groups: 33.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study illustrated a substantial burden of illness with high mortality rates in patients with ASMD, including adults with ASMD type B, in France.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-024-03234-6","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:02:41Z","timestamp":1722891761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acid sphingomyelinase deficiency in France: a retrospective survival study"],"prefix":"10.1186","volume":"19","author":[{"given":"Wladimir","family":"Mauhin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Guffon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie T.","family":"Vanier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"H\u00e9ron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurdag\u00fcl","family":"Uzunhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Levade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymeric","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Pulikottil-Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Laredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-7839","authenticated-orcid":false,"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ASSUR Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Abi-Ward\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Berthoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Cabannes-Hamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Camou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Cathebras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Grobost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Keraen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Lioger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Mehdaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Merlot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine-Louise","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9deric","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Servettaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Stavris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Trouillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"3234_CR1","volume-title":"The online metabolic and molecular bases of inherited disease","author":"EH Schuchman","year":"2019","unstructured":"Schuchman EH, Desnick RJ. Niemann-Pick disease types A and B: Acid sphingomyelinase deficiencies. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The online metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill Education; 2019."},{"key":"3234_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2119\/molmed.2010.00017","volume":"16","author":"JP Desnick","year":"2010","unstructured":"Desnick JP, Kim J, He X, Wasserstein MP, Simonaro CM, Schuchman EH. Identification and characterization of eight novel SMPD1 mutations causing types A and B Niemann-Pick disease. Mol Med. 2010;16:316\u201321.","journal-title":"Mol Med"},{"key":"3234_CR3","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/B978-0-444-59565-2.00041-1","volume":"113","author":"MT Vanier","year":"2013","unstructured":"Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717\u201321.","journal-title":"Handb Clin Neurol"},{"key":"3234_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A, B Niemann-Pick disease. Mol Genet Metab. 2017;120:27\u201333.","journal-title":"Mol Genet Metab"},{"key":"3234_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","volume":"29","author":"SD Kingma","year":"2015","unstructured":"Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29:145\u201357.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3234_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","volume":"12","author":"R Pinto","year":"2004","unstructured":"Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12:87\u201392.","journal-title":"Eur J Hum Genet"},{"key":"3234_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10545-010-9093-7","volume":"33","author":"H Poupetov\u00e1","year":"2010","unstructured":"Poupetov\u00e1 H, Ledvinov\u00e1 J, Bern\u00e1 L, Dvor\u00e1kov\u00e1 L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33:387\u201396.","journal-title":"J Inherit Metab Dis"},{"key":"3234_CR8","first-page":"100344","volume":"19","author":"SJ Chin","year":"2022","unstructured":"Chin SJ, Fuller M. Prevalence of lysosomal storage disorders in Australia from 2009 to 2020. Lancet Reg Health West Pac. 2022;19:100344.","journal-title":"Lancet Reg Health West Pac"},{"key":"3234_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.revmed.2016.10.387","volume":"38","author":"O Lidove","year":"2017","unstructured":"Lidove O, Belmatoug N, Froissart R, Lavigne C, Durieu I, Mazodier K, et al. [Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: a retrospective multicentric study of 28 adult cases]. Rev Med Interne. 2017;38:291\u20139.","journal-title":"Rev Med Interne"},{"key":"3234_CR10","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1542\/peds.2004-0887","volume":"114","author":"MP Wasserstein","year":"2004","unstructured":"Wasserstein MP, Desnick RJ, Schuchman EH, Hossain S, Wallenstein S, Lamm C, et al. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics. 2004;114:e672\u20137.","journal-title":"Pediatrics"},{"key":"3234_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66:228\u201332.","journal-title":"Neurology"},{"key":"3234_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/gim.2017.7","volume":"19","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Dionisi-Vici C, Giugliani R, Hwu P, Lidove O, Lukacs Z, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med. 2017;19:967\u201374.","journal-title":"Genet Med"},{"key":"3234_CR13","volume-title":"GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle Copyright \u00a9 1993\u20132022, University of Washington, Seattle","author":"MP Wasserstein","year":"2021","unstructured":"Wasserstein MP, Schuchman EH. Acid sphingomyelinase deficiency. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle Copyright \u00a9 1993\u20132022, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 2021."},{"key":"3234_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12:41.","journal-title":"Orphanet J Rare Dis"},{"key":"3234_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","volume":"149","author":"MP Wasserstein","year":"2006","unstructured":"Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr. 2006;149:554\u20139.","journal-title":"J Pediatr"},{"key":"3234_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-2003-44668","volume":"34","author":"K Harzer","year":"2003","unstructured":"Harzer K, Rolfs A, Bauer P, Zschiesche M, Mengel E, Backes J, et al. Niemann-Pick disease type A and B are clinically but also enzymatically heterogeneous: pitfall in the laboratory diagnosis of sphingomyelinase deficiency associated with the mutation Q292 K. Neuropediatrics. 2003;34:301\u20136.","journal-title":"Neuropediatrics"},{"key":"3234_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10545-005-5671-5","volume":"28","author":"H Pavl\u016f-Pereira","year":"2005","unstructured":"Pavl\u016f-Pereira H, Asfaw B, Poupctov\u00e1 H, Ledvinov\u00e1 J, Sikora J, Vanier MT, et al. Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis. 2005;28:203\u201327.","journal-title":"J Inherit Metab Dis"},{"key":"3234_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpeds.2004.02.048","volume":"145","author":"MM McGovern","year":"2004","unstructured":"McGovern MM, Pohl-Worgall T, Deckelbaum RJ, Simpson W, Mendelson D, Desnick RJ, et al. Lipid abnormalities in children with types a and B Niemann pick disease. J Pediatr. 2004;145:77\u201381.","journal-title":"J Pediatr"},{"key":"3234_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","volume":"118","author":"D Cassiman","year":"2016","unstructured":"Cassiman D, Packman S, Bembi B, Turkia HB, Al-Sayed M, Schiff M, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab. 2016;118:206\u201313.","journal-title":"Mol Genet Metab"},{"key":"3234_CR20","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2007-3016","volume":"122","author":"MM McGovern","year":"2008","unstructured":"McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122:e341\u20139.","journal-title":"Pediatrics"},{"key":"3234_CR21","unstructured":"XenpozymeTM (olipudase. alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-08-31-18-30-00-2507978. Accessed 25 Dec 2022."},{"key":"3234_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40265-022-01727-x","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Olipudase Alfa: first approval. Drugs. 2022;82:941\u20137.","journal-title":"Drugs"},{"key":"3234_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","volume":"17","author":"GA Diaz","year":"2022","unstructured":"Diaz GA, Giugliani R, Guffon N, Jones SA, Mengel E, Scarpa M, et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results. Orphanet J Rare Dis. 2022;17:437.","journal-title":"Orphanet J Rare Dis"},{"key":"3234_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, Jones SA, Scarpa M, Mengel KE, Giugliani R, Guffon N, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med. 2021;23:1543\u201350.","journal-title":"Genet Med"},{"key":"3234_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results. Genet Med. 2022;24:1425\u201336.","journal-title":"Genet Med"},{"key":"3234_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","volume":"41","author":"MP Wasserstein","year":"2018","unstructured":"Wasserstein MP, Diaz GA, Lachmann RH, Jouvin MH, Nandy I, Ji AJ, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis. 2018;41:829\u201338.","journal-title":"J Inherit Metab Dis"},{"key":"3234_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013;15:618\u201323.","journal-title":"Genet Med"},{"key":"3234_CR28","doi-asserted-by":"crossref","first-page":"101040","DOI":"10.1016\/j.ymgmr.2023.101040","volume":"38","author":"R Pulikottil-Jacob","year":"2024","unstructured":"Pulikottil-Jacob R, Dehipawala S, Smith B, Athavale A, Gusto G, Chandak A, et al. Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: a retrospective chart review study. Mol Genet Metab Rep. 2024;38:101040.","journal-title":"Mol Genet Metab Rep"},{"key":"3234_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-021-01842-0","volume":"16","author":"MM McGovern","year":"2021","unstructured":"McGovern MM, Wasserstein MP, Bembi B, Giugliani R, Mengel KE, Vanier MT, et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis. 2021;16:212.","journal-title":"Orphanet J Rare Dis"},{"key":"3234_CR30","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.3390\/jcm10215029","volume":"10","author":"W Mauhin","year":"2021","unstructured":"Mauhin W, Levade T, Vanier MT, Froissart R, Lidove O. Prevalence of cancer in acid sphingomyelinase deficiency. J Clin Med. 2021;10:5029.","journal-title":"J Clin Med"},{"key":"3234_CR31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.revmed.2010.01.009","volume":"31","author":"C Alizon","year":"2010","unstructured":"Alizon C, Beucher AB, Gourdier AL, Lavigne C. [Type B Niemann Pick disease: clinical description of three patients in a same family]. Rev Med Interne. 2010;31:562\u20135.","journal-title":"Rev Med Interne"},{"key":"3234_CR32","first-page":"117","volume":"15","author":"O Lidove","year":"2015","unstructured":"Lidove O, Sedel F, Charlotte F, Froissart R, Vanier MT. Cirrhosis and liver failure: expanding phenotype of Acid sphingomyelinase-deficient Niemann-Pick disease in adulthood. JIMD Rep. 2015;15:117\u201321.","journal-title":"JIMD Rep"},{"key":"3234_CR33","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ejpn.2017.07.015","volume":"21","author":"O Mercati","year":"2017","unstructured":"Mercati O, Pichard S, Ouach\u00e9e M, Froissart R, Fenneteau O, Roche B, et al. Limited benefits of presymptomatic cord blood transplantation in neurovisceral acid sphingomyelinase deficiency (ASMD) intermediate type. Eur J Paediatr Neurol. 2017;21:907\u201311.","journal-title":"Eur J Paediatr Neurol"},{"key":"3234_CR34","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/bjh.18050","volume":"197","author":"E Portier","year":"2022","unstructured":"Portier E, Talbot A, Nguyen Y, Royer B, Pettazzoni M, Ben Salah I, et al. Multiple myeloma occurring in a case of Niemann-Pick disease type B: a pathophysiological link? Br J Haematol. 2022;197:e53\u20135.","journal-title":"Br J Haematol"},{"key":"3234_CR35","unstructured":"INSEE. 2022 https:\/\/www.insee.fr\/1a9385c5-44ab-4d3e-86c3-5d7933fade0f\u00a0Accessed 23 May 2023."},{"key":"3234_CR36","doi-asserted-by":"publisher","first-page":"107263","DOI":"10.1016\/j.ymgme.2022.107263","volume":"138","author":"M Pettazzoni","year":"2023","unstructured":"Pettazzoni M, Froissart R, Vanier M. Acid sphingomyelinase deficiency: epidemiologic and genetic aspects of a French cohort 1974\u20132021. Mol Genet Metab. 2023;138:107263.","journal-title":"Mol Genet Metab"},{"key":"3234_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1086\/345074","volume":"71","author":"CM Simonaro","year":"2002","unstructured":"Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype\/phenotype correlations. Am J Hum Genet. 2002;71:1413\u20139.","journal-title":"Am J Hum Genet"},{"key":"3234_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/humu.22923","volume":"37","author":"S Zampieri","year":"2016","unstructured":"Zampieri S, Filocamo M, Pianta A, Lualdi S, Gort L, Coll MJ, et al. SMPD1 mutation update: database and comprehensive analysis of published and novel variants. Hum Mutat. 2016;37:139\u201347.","journal-title":"Hum Mutat"},{"key":"3234_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","volume":"18","author":"T Geberhiwot","year":"2023","unstructured":"Geberhiwot T, Wasserstein M, Wanninayake S, Bolton SC, Dardis A, Lehman A, et al. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types a, B and A\/B). Orphanet J Rare Dis. 2023;18:85.","journal-title":"Orphanet J Rare Dis"},{"key":"3234_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.beem.2014.10.002","volume":"29","author":"EH Schuchman","year":"2015","unstructured":"Schuchman EH, Wasserstein MP. Types a, B Niemann-pick disease. Best Pract Res Clin Endocrinol Metab. 2015;29:237\u201347.","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03234-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03234-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03234-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T02:48:47Z","timestamp":1732589327000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03234-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03234-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and all subsequent amendments, the guidelines for Good Epidemiology Practice, Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology, all national laws and regulations of France (where the study was performed), and any applicable guidelines. The necessary regulatory submission (ethics committee) was performed in accordance with local regulations, including local data protection regulations. A written and signed informed consent was obtained from alive participants or their legal representatives. The study was approved by Health Data Hub on 9th March, 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WM has received honoraria from Amicus, Sanofi, Chiesi and Takeda; consultation fees from Chiesi and Sanofi. NG has received honoraria or consultation fees from Sanofi, Ultragenyx, and Chiesi; PI in ASCEND-PED, a Sanofi-sponsored trial. MTV has received honoraria from Orphazyme, Orchard Therapeutics, and Sanofi. RF has received honoraria from Sanofi, Takeda, and Chiesi; travel fees and accommodation from Amicus. AC has received honoraria from Sanofi. CD has received honoraria from Ultragenyx and Sanofi. CL has received honoraria or consultation fees from Sanofi and Boehringer Ingelheim. BH has received honoraria from Takeda and Orchard; travel fees and accommodation from Chiesi, PTC Therapeutics; PI in trials sponsored by JR Pharmaceuticals, Chiesi, Orphazyme, Lysogene and Mallincrodt. NB has received consultation fees for speaking, education, clinical trials and research from Sanofi and Takeda. YU has received consulting fees and honoraria for speaking, or educational events from Boehringer-Ingelheim, Sanofi, GSK, Pfizer, and Oxyvie. DL has participated in a Board with Sanofi. TL has received consulting fees from Sanofi and Chiesi. AD and RP-J are employees and may hold stocks and\/or stock options in Sanofi. FL was an employee of Sanofi at the time of study conduct. SP has received honoraria from Sanofi and Biomarin; travel fees and accommodation from Sanofi, Biomarin and Takeda. OL has received honoraria from Amicus, Sanofi, and Chiesi; PI in ASCEND, a Sanofi-sponsored trial; consultation fees from Amicus and Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}